Quick Win by the Algorithm: FDA approval imminent for NKTR

Quick Win by the Algorithm

On March 13th, 2017,  the I Know First algorithm had predicted a bullish forecast for Nektar Therapeutics (NKTR). It had a signal of 82.49 and a predictability of 0.02. The company reported gains of 44.13% in just 7 days and therefore, a quick win by the algorithm.


Nektar Therapeutics (NKTR) is an American biopharmaceutical company. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies. The company developed the world’s first inhalable non-injectable insulin, Exubera.


Nektar Therapeutics (NKTR) opened the week a little over $15 a share. After results were released following its lead trial. The share soared to $22, a rise of almost 45%

The questions begs, what could cause such a drastic increase in stock price?

Opioid abuse, specifically in the US is a big issue. There is great market potential for a company to bring a safe alternative to addictive opioid therapy. NKTR just released data that came from a phase 3 of their new drug NKTR-181. Phase 3 was designed in order to showcase the effective pain relief of NKTR-181 over placebo. As well as maintaining a clean, safe and tolerable profile.

With data results as expected in favour of the new drug, there is now little doubt surrounding its FDA approval. Hence the sudden spike in share price.

It seems the next move for Nektar is to find a suitable partner that will foot the bill and help them bring the drug to market. This is not an uncommon move for Nektar, as it has exercised this model previously. The only question that remains, is who to partner with.


This bullish forecast on NKTR was sent to current I Know First subscribers on March 13th, 2017. 

Before making any trading decisions, consult the latest forecast as the algorithm constantly updates predictions daily. While the algorithm can be used for intra-day trading the predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.